Scorpex, Inc., an emerging leader of industrial, hazardous and toxic waste disposal services in the Baja Mexico/California region, today announced additional details of its recently announced major equipment contract signed with International Environmental Technologies, Inc. (“IET”) for the acquisition and installation of waste gasification/thermal oxidation equipment as well as a license to use the technology.
Scorpex has agreed to a total purchase price of USD$30,000,000. As terms of the agreement, the purchase price will be paid in four payments: USD$9,000,000 upon the release of funds from the lender; USD$9,000,000 upon IET’s delivery to Scorpex of a certification that the shop drawings and other engineering work for the installation of the Equipment has been completed; USD$9,000,000 upon IET’s delivery to Scorpex of a certification that the erection of the steel framework for all two units has been completed; and USD$3,000,000 upon the final check out, testing of the unit and commissioning.
IET will install the equipment, train supervisory personnel to operate and maintain the equipment, provide a set of spare parts and issue certificates of completion. In addition, IET will provide a warranty for the equipment installed, ensuring that the equipment will be free from defects in materials and workmanship. If malfunction is reported within the warranty period, IET will repair or replace the defective or non-conforming part at no charge to Scorpex.
As stated in yesterday’s press release, IET’s proprietary technology can process waste simultaneously without presorting. The system is virtually silent and without odors, capable of reducing waste volume 95%. The system also features a lower capital investment than competition as well as lower operating costs. With an average construction time of only six to twelve months, Scorpex said it anticipates commencing full operations before the previously projected time frame.
Chief Executive Officer Joseph Caywood commented, “As I said previously, we have made remarkable progress and are very excited to be moving forward so quickly with our business strategy. Signing such a major equipment contract at the dawn of establishing our first waste disposal and processing plant is yet another strong vote of confidence by others who have chosen to join our initiative to address Mexico’s growing demand for industrial, hazardous and toxic waste management.”
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, July 28, 2011
First Quarter 2011 Results Reported by Mastech Holdings Inc. (MHH)
Pittsburgh-based Mastech Holdings Inc. is a nationwide provider of information technology and specialized healthcare staffing services to hospitals and other healthcare facilities. The company announced its financial results for the first quarter ended March 31, 2011.
Revenues for the period came in at $19.9 million and represented a 27 percent increase over the corresponding quarter of 2010. Gross profit for the first quarter of 2011 totaled $3.8 million or approximately $800,000 above the gross profit for the first quarter of last year. Consolidated net income for the first quarter of 2011 totaled $37,000 or $0.01 per diluted share versus last year’s figure of $63,000 or $0.02 per diluted share.
Demand for Mastech’s IT staffing services remained solid in the first quarter as the company increased its billable consultant headcount by 3.5 percent and established IT branch operations in Chicago. According to Mastech, market conditions in the healthcare industry continue to show signs of improvement. It was this improvement which led to the company achieving sequential revenue growth for the third consecutive quarter.
Mastech’s balance sheet remains strong with $4.8 million of cash on hand and no outstanding bank debt. The company also has access to $8.7 million of credit under its existing revolving credit facility. For additional information on Mastech Holdings, please visit its website at www.mastech.com.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Revenues for the period came in at $19.9 million and represented a 27 percent increase over the corresponding quarter of 2010. Gross profit for the first quarter of 2011 totaled $3.8 million or approximately $800,000 above the gross profit for the first quarter of last year. Consolidated net income for the first quarter of 2011 totaled $37,000 or $0.01 per diluted share versus last year’s figure of $63,000 or $0.02 per diluted share.
Demand for Mastech’s IT staffing services remained solid in the first quarter as the company increased its billable consultant headcount by 3.5 percent and established IT branch operations in Chicago. According to Mastech, market conditions in the healthcare industry continue to show signs of improvement. It was this improvement which led to the company achieving sequential revenue growth for the third consecutive quarter.
Mastech’s balance sheet remains strong with $4.8 million of cash on hand and no outstanding bank debt. The company also has access to $8.7 million of credit under its existing revolving credit facility. For additional information on Mastech Holdings, please visit its website at www.mastech.com.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
California Community Bank (CABK) Releases Unaudited Second Quarter 2011 Financial Results
On Wednesday, California Community Bank released their unaudited second quarter 2011 financial results. For the second quarter of 2011, they reported net income of $212,000, or basic earnings per share of 10 cents. This is in comparison to net income of $338,000, or basic earnings per share of 16 cents, for the comparable period of the prior year. Net income for the first six months of the year was $381,000, or basic earnings per share of 18 cents, versus net income of $598,000, or basic earnings per share of 28 cents, for the first six months of 2010.
California Community Bank’s provision for income taxes amounted to $295,000 for the six-month period ending June 30, 2011. Their earnings were not fully taxable for the comparable period last year and therefore, they allocated no provision. Concerning pre-tax income, the Bank reported $676,000 for the first half of 2011. This is in comparison to $598,000 for the comparable period in 2010, a year-over-year increase of $78,000, or 13 percent, between the two periods.
They finished the second quarter of 2011 with an asset base of $235,705,000. This represents an increase of $17,149,000, or 8 percent, from the end of June 2010. Total deposits were $209,694,000, up $18,832,000, or 10 percent, over the same period a year prior. As of June 30, 2011, total gross loans net of deferred fees (the primary revenue driver for the Bank) stood at $154,157,000. This is in comparison to $158,465,000 at June 30, 2010, a decrease of $4,308,000, or 3 percent.
Mr. Larry D. Hartwig, CEO, commented, “We are pleased to report that a combination of reduced funding costs and strategic loan portfolio management continues to be effective in delivering improved operating results. Despite an increase in non-performing loans, asset quality remained at a very manageable level during this slowly healing economy – and the organic growth of core deposits drove a 27 percent year-over-year reduction in our interest expense.
“Overall, we ended the quarter with over $235 million in total assets and recorded a small increase in year-to-date net interest income on reduced loan outstandings. The year-to-date story continues to reflect that profitability has been limited by excess liquidity, quality loan growth is still a challenge, operating costs are well controlled, and there are few attractive investment alternatives in securities. Our efforts did allow us to experience moderate loan growth during the first half of 2011, although throughout most of 2010, loan demand reflected the prevailing negative economic headwinds contributing toward the year-over-year decline in our loan portfolio. All of this is evidence of a sluggish recovery in the local economy. Management remains focused on normalized profitability and continued expense control for the year ahead. We have confidence in the core strengths of our franchise and continue to aggressively manage loan quality with the expectation of economic growth obtaining greater traction in the future.
Mr. Hartwig commented further, “Capital ratios remain very strong and we continue to seek quality loan originations to augment our conservatively underwritten loan portfolio. In this economy, we also know that loan growth must be driven by market share gains rather than by increased economic activity. We also want to recognize the valuable contributions of our highly professional staff in making California Community Bank a premier bank committed to providing our customers with ‘Real Solutions. Personally Delivered’.”
Headquartered in Escondido, CA, California Community Bank is a full service commercial bank. Currently, they operate four branches; these are in Escondido, Encinitas, San Diego, and Vista, California. The Bank opened for business on August 11, 2003, and on November 26, 2003, they went public on the Over The Counter Bulletin Board (OTCBB).
For more information visit: www.calcommunitybank.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
California Community Bank’s provision for income taxes amounted to $295,000 for the six-month period ending June 30, 2011. Their earnings were not fully taxable for the comparable period last year and therefore, they allocated no provision. Concerning pre-tax income, the Bank reported $676,000 for the first half of 2011. This is in comparison to $598,000 for the comparable period in 2010, a year-over-year increase of $78,000, or 13 percent, between the two periods.
They finished the second quarter of 2011 with an asset base of $235,705,000. This represents an increase of $17,149,000, or 8 percent, from the end of June 2010. Total deposits were $209,694,000, up $18,832,000, or 10 percent, over the same period a year prior. As of June 30, 2011, total gross loans net of deferred fees (the primary revenue driver for the Bank) stood at $154,157,000. This is in comparison to $158,465,000 at June 30, 2010, a decrease of $4,308,000, or 3 percent.
Mr. Larry D. Hartwig, CEO, commented, “We are pleased to report that a combination of reduced funding costs and strategic loan portfolio management continues to be effective in delivering improved operating results. Despite an increase in non-performing loans, asset quality remained at a very manageable level during this slowly healing economy – and the organic growth of core deposits drove a 27 percent year-over-year reduction in our interest expense.
“Overall, we ended the quarter with over $235 million in total assets and recorded a small increase in year-to-date net interest income on reduced loan outstandings. The year-to-date story continues to reflect that profitability has been limited by excess liquidity, quality loan growth is still a challenge, operating costs are well controlled, and there are few attractive investment alternatives in securities. Our efforts did allow us to experience moderate loan growth during the first half of 2011, although throughout most of 2010, loan demand reflected the prevailing negative economic headwinds contributing toward the year-over-year decline in our loan portfolio. All of this is evidence of a sluggish recovery in the local economy. Management remains focused on normalized profitability and continued expense control for the year ahead. We have confidence in the core strengths of our franchise and continue to aggressively manage loan quality with the expectation of economic growth obtaining greater traction in the future.
Mr. Hartwig commented further, “Capital ratios remain very strong and we continue to seek quality loan originations to augment our conservatively underwritten loan portfolio. In this economy, we also know that loan growth must be driven by market share gains rather than by increased economic activity. We also want to recognize the valuable contributions of our highly professional staff in making California Community Bank a premier bank committed to providing our customers with ‘Real Solutions. Personally Delivered’.”
Headquartered in Escondido, CA, California Community Bank is a full service commercial bank. Currently, they operate four branches; these are in Escondido, Encinitas, San Diego, and Vista, California. The Bank opened for business on August 11, 2003, and on November 26, 2003, they went public on the Over The Counter Bulletin Board (OTCBB).
For more information visit: www.calcommunitybank.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Total Apparel Group Inc. (TLAG) is “One to Watch”
Total Apparel Group, Inc. is a licensing and brand management partner for highly diversified, pre-eminent international sports, entertainment and lifestyle brands in North America. The Company has an extensive sales and distribution network. They facilitate sales as a master distributor of branded products with an emphasis on the apparel, footwear and accessory sectors. Total Apparel Group Inc. has their corporate headquarters in New York, New York.
The Company is focusing on building a collection of market-leading national and international registered trademarks via joint ventures, master licensing/distribution agreements and acquisitions. Their goal is to increase the value of their trademarks by expanding the branded products market positions through an internal sales force, a network of strong licensees, distributors and Company-owned and operated retail outlets.
Earlier this month, Total Apparel Group, Inc. announced that their wholly owned subsidiary, Total Licensing, Inc. (TLI), signed a five-year lease for new showroom space at 230 West 39th Street, located in the heart of Manhattan’s Fashion District. The 1,850-square-foot space on the 6th floor will serve as TLI’s primary East Coast showroom for SKECHERS Time Instruments and additional licensed properties. Located between Seventh and Eighth Avenues, 230 West 39th Street is a 16-story, 59,488-square-foot office building.
Janon Costley, Chief Executive Officer, Total Apparel Group, Inc., said, “We are thrilled with the new showroom at 230 West 39th Street, which offers ideal space to showcase SKECHERS Time Instruments in a prime location in the Fashion District.”
TLI is a service orientated company that handles licensing and brand extension opportunities for new and/or existing licensed properties, brands or companies. They work to expand a given product/brands market position in the North American marketplace and consequently increase the overall value of the individual trademark.
Total Apparel Group Inc. recently announced TLI’s relationship with Glamm Industries, LLC, to develop and market SKECHERS Time Instruments, which will be available in retailers throughout the U.S. in the Fall of 2011.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Company is focusing on building a collection of market-leading national and international registered trademarks via joint ventures, master licensing/distribution agreements and acquisitions. Their goal is to increase the value of their trademarks by expanding the branded products market positions through an internal sales force, a network of strong licensees, distributors and Company-owned and operated retail outlets.
Earlier this month, Total Apparel Group, Inc. announced that their wholly owned subsidiary, Total Licensing, Inc. (TLI), signed a five-year lease for new showroom space at 230 West 39th Street, located in the heart of Manhattan’s Fashion District. The 1,850-square-foot space on the 6th floor will serve as TLI’s primary East Coast showroom for SKECHERS Time Instruments and additional licensed properties. Located between Seventh and Eighth Avenues, 230 West 39th Street is a 16-story, 59,488-square-foot office building.
Janon Costley, Chief Executive Officer, Total Apparel Group, Inc., said, “We are thrilled with the new showroom at 230 West 39th Street, which offers ideal space to showcase SKECHERS Time Instruments in a prime location in the Fashion District.”
TLI is a service orientated company that handles licensing and brand extension opportunities for new and/or existing licensed properties, brands or companies. They work to expand a given product/brands market position in the North American marketplace and consequently increase the overall value of the individual trademark.
Total Apparel Group Inc. recently announced TLI’s relationship with Glamm Industries, LLC, to develop and market SKECHERS Time Instruments, which will be available in retailers throughout the U.S. in the Fall of 2011.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
SANUWAVE Health, Inc. (SNWV) is “One to Watch”
SANUWAVE Health, Inc. is a regenerative medicine company headquartered in Alpharetta, Georgia. The Company is focusing on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. Their product and product candidate portfolio activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration.
SANUWAVE intends to apply their PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. The Company’s lead product candidate for the worldwide wound care market is dermaPACE. This product has CE marking for the treatment of the skin and subcutaneous soft tissue. It recently completed its positive pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the United States for the treatment of diabetic foot ulcers.
The Company researches, designs, manufactures, markets and services their products globally. They believe they have demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through their U.S. Class III PMA approved Ossatron® device. They also believe they have demonstrated that this technology is safe and effective in stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of their Ossatron, Evotron™ and orthoPACE® devices in Europe.
Yesterday, SANUWAVE Health, Inc. announced that their dermaPACE® is the subject of a Continuing Medical Education (CME) accredited presentation at the American Podiatric Medical Association (APMA) 2011 National Meeting being held July 26-28, 2011 in Boston. The presentation is titled “Pulsed Acoustic Cellular Expression Technology in the Treatment of Diabetic Foot Ulcers: A Sham-controlled, Double-blinded, Randomized Clinical Trial.” The presentation highlights and expands on the dermaPACE pivotal Phase III clinical trial results.
Christopher M. Cashman, President and Chief Executive Officer of SANUWAVE Health, Inc., said, “The results for dermaPACE are compelling. Diabetic foot ulcers treated with dermaPACE, in general, immediately stabilized and did not worsen. These ulcers quickly reduced in size and continued to full closure in a significantly greater proportion than ulcers in the comparative Sham-control group. Ulcers closed with dermaPACE didn’t tend to recur, and dermaPACE procedures were shown to be safe and were associated with a lower overall incidence of infection.”
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
SANUWAVE intends to apply their PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. The Company’s lead product candidate for the worldwide wound care market is dermaPACE. This product has CE marking for the treatment of the skin and subcutaneous soft tissue. It recently completed its positive pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the United States for the treatment of diabetic foot ulcers.
The Company researches, designs, manufactures, markets and services their products globally. They believe they have demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through their U.S. Class III PMA approved Ossatron® device. They also believe they have demonstrated that this technology is safe and effective in stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of their Ossatron, Evotron™ and orthoPACE® devices in Europe.
Yesterday, SANUWAVE Health, Inc. announced that their dermaPACE® is the subject of a Continuing Medical Education (CME) accredited presentation at the American Podiatric Medical Association (APMA) 2011 National Meeting being held July 26-28, 2011 in Boston. The presentation is titled “Pulsed Acoustic Cellular Expression Technology in the Treatment of Diabetic Foot Ulcers: A Sham-controlled, Double-blinded, Randomized Clinical Trial.” The presentation highlights and expands on the dermaPACE pivotal Phase III clinical trial results.
Christopher M. Cashman, President and Chief Executive Officer of SANUWAVE Health, Inc., said, “The results for dermaPACE are compelling. Diabetic foot ulcers treated with dermaPACE, in general, immediately stabilized and did not worsen. These ulcers quickly reduced in size and continued to full closure in a significantly greater proportion than ulcers in the comparative Sham-control group. Ulcers closed with dermaPACE didn’t tend to recur, and dermaPACE procedures were shown to be safe and were associated with a lower overall incidence of infection.”
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, July 27, 2011
Sanuwave Health, Inc.’s (SNWV) dermaPACE® To Be Highlighted in CME Presentation at APMA 2011
Sanuwave Health Inc., a medical technology company, focuses on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal, and vascular structures. Today the company announced dermaPACE® will be highlighted in a Continuing Medical Education (CME) accredited presentation at the American Podiatric Medical Association (APMA) 2011, which is to be held July 26-28 in Boston. Podiatrists are doctors who provide treatment for conditions that affect the ankle and foot, which includes soft tissue disorders such as diabetic foot ulcers.
The presentation, which is titled “Pulsed Acoustic Cellular Expression Technology in the Treatment of Diabetic Foot Ulcers: A Sham-controlled, Double-blinded, Randomized Clinical Trial,” will be held on Thursday, July 28 from 2:30-3:00 p.m. Eastern time. The presentation will showcase and expand upon the dermaPACE pivotal phase III clinical trial results, which includes: dermaPACE subjects reached a statistical significance in 100% wound closure compared to Sham-control beginning at 20 weeks (p=0.018) and continuing on through 24 weeks (p=0.022); within the 6 weeks that followed the initial dermaPACE procedure, and consistently throughout the 24-week analysis period, dermaPACE has drastically decreased the size of the ulcer compared with subjects randomized to receive Sham-control; dermaPACE was linked with an extremely low rate of ulcer recurrence at a 24 week mark (4.5%); and dermaPACE was shown to have an excellent safety profile, which includes a reduction in infection.
The presentation will be delivered by Vickie R. Driver, DPM, MS, FACFAS; Associate Professor of Surgery; Director, Clinical Research Limb Preservation and Wound Healing; and Director, Research Fellowship and International Scholars Program, Boston University Medical Campus and Boston University School of Medicine, and one of the principal investigators on the recently concluded Phase III, Investigational Device Exemption (IDE) clinical trial for dermaPACE for the treatment of diabetic foot ulcers.
SANUWAVE Health will be displaying dermaPACE and the strongly compelling clinical data from its Phase III clinical trial about the diabetic foot ulcers at Exhibit Booth #620 throughout the meeting.
Christopher M. Cashman, President and Chief Executive Officer of SANUWAVE, said, “The results for dermaPACE are compelling. Diabetic foot ulcers treated with dermaPACE, in general, immediately stabilized and did not worsen. These ulcers quickly reduced in size and continued to full closure in a significantly greater proportion than ulcers in the comparative Sham-control group. Ulcers closed with dermaPACE didn’t tend to recur, and dermaPACE procedures were shown to be safe and were associated with a lower overall incidence of infection.”
“We already know that dermaPACE procedures can be delivered at a much lower cost to the healthcare system than existing advanced wound treatment modalities – and with improved ease of use and convenience for both clinicians and patients. These highly positive dermaPACE study results complete the picture and position dermaPACE well for early adoption and widespread utilization. We are pleased to have these results presented in the first nationally accredited CME presentation at an annual scientific meeting,” concluded Mr. Cashman.
For more information on Sanuwave Health, Inc. visit their company website: www.sanuwave.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The presentation, which is titled “Pulsed Acoustic Cellular Expression Technology in the Treatment of Diabetic Foot Ulcers: A Sham-controlled, Double-blinded, Randomized Clinical Trial,” will be held on Thursday, July 28 from 2:30-3:00 p.m. Eastern time. The presentation will showcase and expand upon the dermaPACE pivotal phase III clinical trial results, which includes: dermaPACE subjects reached a statistical significance in 100% wound closure compared to Sham-control beginning at 20 weeks (p=0.018) and continuing on through 24 weeks (p=0.022); within the 6 weeks that followed the initial dermaPACE procedure, and consistently throughout the 24-week analysis period, dermaPACE has drastically decreased the size of the ulcer compared with subjects randomized to receive Sham-control; dermaPACE was linked with an extremely low rate of ulcer recurrence at a 24 week mark (4.5%); and dermaPACE was shown to have an excellent safety profile, which includes a reduction in infection.
The presentation will be delivered by Vickie R. Driver, DPM, MS, FACFAS; Associate Professor of Surgery; Director, Clinical Research Limb Preservation and Wound Healing; and Director, Research Fellowship and International Scholars Program, Boston University Medical Campus and Boston University School of Medicine, and one of the principal investigators on the recently concluded Phase III, Investigational Device Exemption (IDE) clinical trial for dermaPACE for the treatment of diabetic foot ulcers.
SANUWAVE Health will be displaying dermaPACE and the strongly compelling clinical data from its Phase III clinical trial about the diabetic foot ulcers at Exhibit Booth #620 throughout the meeting.
Christopher M. Cashman, President and Chief Executive Officer of SANUWAVE, said, “The results for dermaPACE are compelling. Diabetic foot ulcers treated with dermaPACE, in general, immediately stabilized and did not worsen. These ulcers quickly reduced in size and continued to full closure in a significantly greater proportion than ulcers in the comparative Sham-control group. Ulcers closed with dermaPACE didn’t tend to recur, and dermaPACE procedures were shown to be safe and were associated with a lower overall incidence of infection.”
“We already know that dermaPACE procedures can be delivered at a much lower cost to the healthcare system than existing advanced wound treatment modalities – and with improved ease of use and convenience for both clinicians and patients. These highly positive dermaPACE study results complete the picture and position dermaPACE well for early adoption and widespread utilization. We are pleased to have these results presented in the first nationally accredited CME presentation at an annual scientific meeting,” concluded Mr. Cashman.
For more information on Sanuwave Health, Inc. visit their company website: www.sanuwave.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Trius Therapeutics, Inc. (TSRX) Receives $25 Million Upfront from Bayer Healthcare for Collaboration on Antibiotic to Fight Bacterial Infectious...
Trius Therapeutics, Inc. (TSRX) Receives $25 Million Upfront from Bayer Healthcare for Collaboration on Antibiotic to Fight Bacterial Infectious Diseases in Emerging Markets
Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that Bayer Healthcare will pay $25 million upfront as well as 25 percent of future development costs to develop and commercialize Trius’s lead Phase 3 antibiotic, torezolid phosphate (torezolid). In addition, Trius is eligible to receive up to $69 million upon the achievement of certain development, regulatory and commercial milestones and will receive double-digit royalties on net sales of torezolid in the licensed territory.
The two companies aim to get global approval for torezolid as the drug of choice to combat acute bacterial skin and skin structure infections (ABSSSI) and pneumonia. Bayer will get the opportunity to sell the antibiotic in all countries in Asia including China and Japan, Africa, Latin America and the Middle East, but excluding North and South Korea. Trius will maintain full development and commercialization rights for the product outside those areas including the United States, Canada and the European Union.
“Bayer’s commitment to the infectious disease area and their depth and breadth of experience in these markets makes them an ideal partner for Trius,” Jeffrey Stein, Ph.D., President and CEO of Trius stated in today’s press release. “At the same time, consistent with our strategy, we have retained rights to the U.S. and E.U. markets where life-threatening infections from MRSA and other gram positive pathogens continue to be a significant concern.”
The antibiotic , torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI, the first such trial to be initiated under a Special Protocol Assessment (SPA). Trius holds an exclusive license to torezolid phosphate for territories outside of North and South Korea from Dong-A Pharmaceuticals. In addition to the company’s torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria.
“Bacterial infectious diseases represent one of the largest therapeutic areas in China and continue to grow rapidly there and in other emerging markets. This collaboration is a key element in our strategy of bringing innovative medicines to patients, especially in emerging markets,” Dr. Jorg Reinhardt, Chairman of the Board of Management of Bayer HealthCare, said in the press release.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.
For more information, visit www.triusrx.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that Bayer Healthcare will pay $25 million upfront as well as 25 percent of future development costs to develop and commercialize Trius’s lead Phase 3 antibiotic, torezolid phosphate (torezolid). In addition, Trius is eligible to receive up to $69 million upon the achievement of certain development, regulatory and commercial milestones and will receive double-digit royalties on net sales of torezolid in the licensed territory.
The two companies aim to get global approval for torezolid as the drug of choice to combat acute bacterial skin and skin structure infections (ABSSSI) and pneumonia. Bayer will get the opportunity to sell the antibiotic in all countries in Asia including China and Japan, Africa, Latin America and the Middle East, but excluding North and South Korea. Trius will maintain full development and commercialization rights for the product outside those areas including the United States, Canada and the European Union.
“Bayer’s commitment to the infectious disease area and their depth and breadth of experience in these markets makes them an ideal partner for Trius,” Jeffrey Stein, Ph.D., President and CEO of Trius stated in today’s press release. “At the same time, consistent with our strategy, we have retained rights to the U.S. and E.U. markets where life-threatening infections from MRSA and other gram positive pathogens continue to be a significant concern.”
The antibiotic , torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI, the first such trial to be initiated under a Special Protocol Assessment (SPA). Trius holds an exclusive license to torezolid phosphate for territories outside of North and South Korea from Dong-A Pharmaceuticals. In addition to the company’s torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria.
“Bacterial infectious diseases represent one of the largest therapeutic areas in China and continue to grow rapidly there and in other emerging markets. This collaboration is a key element in our strategy of bringing innovative medicines to patients, especially in emerging markets,” Dr. Jorg Reinhardt, Chairman of the Board of Management of Bayer HealthCare, said in the press release.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.
For more information, visit www.triusrx.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
